BillionToOne, Inc. (BLLN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Are Medical Stocks Lagging BillionToOne, Inc. (BLLN) This Year?
Here is how BillionToOne (BLLN) and Concentra Group (CON) have performed compared to their sector so far this year.
Baron Health Care Fund Q1 2026 Portfolio Activity
During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.
Does BillionToOne (BLLN) Have the Potential to Rally 37% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 37% in BillionToOne (BLLN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 25.63% Upside in BillionToOne (BLLN): Here's What You Should Know
The mean of analysts' price targets for BillionToOne (BLLN) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript
BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript
BillionToOne: Delivering And Lagging At The Same Time
BillionToOne delivers strong growth in molecular diagnostics, achieving profitability and raising 2026 revenue guidance to $430–$445 million. BillionToOne's Q4 sales rose 113% to $96.1 million, driven by prenatal testing; oncology growth was slower sequentially but remains a long-term diversification lever. I view current guidance as conservative, with recent product launches and coverage deals not fully reflected in the outlook, supporting further upside potential.
BillionToOne (BLLN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for BillionToOne (BLLN) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
BillionToOne, Inc. (BLLN) Q3 2025 Earnings Call Transcript
BillionToOne, Inc. ( BLLN ) Q3 2025 Earnings Call December 9, 2025 4:30 PM EST Company Participants David Deichler Oguzhan Atay - Co-Founder, Chairman & CEO Ross Taylor - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG, LLC, Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division David Westenberg - Piper Sandler & Co., Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Presentation Operator BillionToOne Third Quarter 2025 Earnings Call.
